Banyu, Maruho Receive NHI Approval For Oral Scabies Medication
Main Category: DermatologyArticle Date: 27 Aug 2006 - 0:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Health Professional: | ![]() |
|
| Article Opinions: | 0 posts |
Banyu Pharmaceutical and Maruho Co., Ltd. have announced that an additional indication of Stromectol Tablets 3mg - generic name ivermectin - has been approved for the administration for scabies treatment in the Nippon Health Insurance (NHI) system, alleviating patients' burden to pay for the drug from themselves.
Banyu retains approval for the manufacturing and marketing Stromectol in Japan, but has transfered sales rights to Maruho.
Stromectol joins with glutamatergic chloride ion channels, increasing the permeability of the cell membrane to chloride ions which kills parasites. Presently, no effective oral drug has been introduced to treat scabies, so the addition of oral drug Stromectol Tablets 3mg, has been encouraged by the health industry in Japan.
By Chris Lui, JCN Staff Writer
Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.
JCN
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |





